

**Vaxon-Biotech to Present Latest Clinical Data
of its Vx-001 Cancer Vaccine
at the AACR 97th Annual Meeting**

P
R
E
S
S

R
E
L
E
A
S
E

Evry-Genopole, France, Mars 14, 2006 – Vaxon-Biotech announces that most recent clinical data from the Vx-001 cancer vaccine trial will be presented at the AACR 97th Annual Meeting by Dr Kostas Kosmatopoulos, Chief Scientific Officer of Vaxon-Biotech. The meeting will take place in Washington DC, April 1-5, 2006.

About Vaxon-Biotech

Vaxon Biotech, founded in early 2004 and based in Evry Genopole - France, is a product-driven biopharmaceutical company focusing on the discovery and development of innovative vaccines for the treatment of cancer. The first two products under development, Vx-001 and Vx-006, are novel treatments for solid tumors. For more information, go to www.vaxon-biotech.com.

Contacts

Philippe Berthon, PhD
CEO
+33(0)160789210
pberthon@vaxon-biotech.com